NICE recommends Olumiant (baricitinib) to treat rheumatoid arthritis.- Eli Lilly
The National Institute for Health and Care Excellence (NICE) in draft guidelines has recommended, JAK inhibitor, Olumiant (baricitinib) from Eli Lilly as an option for rheumatoid arthritis patients whose disease has responded inadequately to therapy with disease modifying drugs (DMARDS).
In the Phase III RA-BEAM trial results showed that baricitinib scored significantly better than placebo on the ACR20 response, a standard clinical measure that represents at least a 20 percent improvement in RA disease activity, as well as demonstrating superiority to Humira (adalimumab) from AbbVie. After 24 weeks, the drug was also superior to placebo in preventing progressive radiographic structural joint damage, and its treatment effects were maintained through 52 weeks of therapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins